Search research articles
Contact Us
Filters
Showing results (51-60 of 68) with videos related to
Page
of 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
April 26, 2021
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors
Francesca Corti, Sara Lonardi, Rossana Intini, et al.
The Oncologist
|
August 6, 2021
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma
Lorenza Di Guardo, Giovanni Randon, Francesca Corti, et al.
British Journal of Cancer
|
November 23, 2021
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study
Paolo Manca, Salvatore Corallo, Sara Lonardi, et al.
Cancers
|
March 12, 2020
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer
Claudio Vernieri, Michele Prisciandaro, Federico Nichetti, et al.
BMC Cancer
|
September 26, 2023
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial
Francesca Corti, Maria Pia Brizzi, Vito Amoroso, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2021
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Filippo Pietrantonio, Sara Lonardi, Francesca Corti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2023
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Claire Gallois, Matteo Landi, Julien Taieb, et al.
The Oncologist
|
May 6, 2020
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
Filippo Pietrantonio, Fotios Loupakis, Giovanni Randon, et al.
Journal for Immunotherapy of Cancer
|
April 14, 2021
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Giovanni Fucà, Francesca Corti, Margherita Ambrosini, et al.
British Journal of Cancer
|
June 6, 2022
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Roberto Moretto, Andrew Elliott, Daniele Rossini, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 68) with videos related to
Sort By:
Page
of 7
European Journal of Cancer (Oxford, England : 1990)
|
April 26, 2021
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors
Francesca Corti, Sara Lonardi, Rossana Intini, et al.
The Oncologist
|
August 6, 2021
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma
Lorenza Di Guardo, Giovanni Randon, Francesca Corti, et al.
British Journal of Cancer
|
November 23, 2021
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study
Paolo Manca, Salvatore Corallo, Sara Lonardi, et al.
Cancers
|
March 12, 2020
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer
Claudio Vernieri, Michele Prisciandaro, Federico Nichetti, et al.
BMC Cancer
|
September 26, 2023
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial
Francesca Corti, Maria Pia Brizzi, Vito Amoroso, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2021
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Filippo Pietrantonio, Sara Lonardi, Francesca Corti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2023
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Claire Gallois, Matteo Landi, Julien Taieb, et al.
The Oncologist
|
May 6, 2020
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
Filippo Pietrantonio, Fotios Loupakis, Giovanni Randon, et al.
Journal for Immunotherapy of Cancer
|
April 14, 2021
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Giovanni Fucà, Francesca Corti, Margherita Ambrosini, et al.
British Journal of Cancer
|
June 6, 2022
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Roberto Moretto, Andrew Elliott, Daniele Rossini, et al.
Page
of 7